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RUNNING TITLE: MCID; chronic refractory breathlessness 
ABSTRACT 
Context: Clinically important differences in chronic refractory breathlessness are ill-defined, 
but important in clinical practice and trial design. 
 Objectives: To estimate the clinical relevance of differences in breathlessness intensity using 
distribution and patient anchor methods. 
Methods: A retrospective data analysis from 213 datasets from four clinical trials for 
refractory breathlessness. Linear regression was used to explore the relationship between 
study effect size and change in breathlessness score (0 – 100mm visual analogue scale) and to 
estimate the change in score equivalent to small, moderate and large effect sizes. 
Pooled individual blinded patient preference data from three randomized controlled trials 
were analysed.  The difference between the mean change in day 4 minus baseline scores 
between preferred and non-preferred arms was calculated.  
Results: There was a strong relationship between change in score and effect size, (p=0.001; 
R2=0.98). Values for small, moderate and large effects were −5.5mm, −11.3mm and 
−18.2mm. The participant preference change in score was −9mm (95% CI −15.8 to −2.1) (p 
= 0.008). 
Conclusions: This larger dataset supports a clinically important difference of 10mm. Studies 
should be powered to detect this difference. 
 
WORD COUNT: 181 




Chronic refractory breathlessness is a challenging symptom for those who experience it, their 
caregivers and clinicians.  Assessment sufficient to monitor clinical benefit and for clinical 
trial outcome measurement is difficult because of the multi-factorial, subjective nature of the 
symptom (1-5),  demonstrated by the plethora of measurement tools . There is consensus that 
the 0 -100mm visual analogue scale [VAS], 0 – 10 numerical rating scale [NRS] and 
modified Borg scale are appropriate uni-dimensional measures of chronic breathlessness 
intensity. (3;5;6) Despite this, there are few data-derived estimates of the minimal clinically 
important difference (MCID) for chronic refractory breathlessness which is needed to design 
studies with adequate  power to determine a statistically and clinically significant change. 
The MCID, different from a statistically significant difference, is defined as the change in a 
breathlessness intensity score discernable to a patient as indicative of improvement or 
deterioration.(7)  
There are two main methods of identifying an MCID for an outcome measure; distribution 
and anchor-based. A full description is beyond the scope of this paper, but useful summary 
discussions are available.(8;9) 
Distribution based calculation of MCID in chronic breathlessness 
The effect size (change after intervention divided by standard deviation of baseline scores) 
can be used as a statistical analysis method to determine the lowest meaningful detectable 
difference based on the underlying variability of the reported data. The smaller the group data 
variability, the greater the “clinical precision” in the change as detected by the individuals 
studied. Furthermore, if there is a true relationship between change in measure and effect 
size, then different study populations should have a similar level of precision over the 
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detection of the change in measure under study. However, it can be difficult to judge whether 
such detectable differences are considered relevant by the patients concerned. 
Anchor-based methods of MCID in breathlessness 
A patient rated global impression of change can provide an anchor to help define a small, 
moderate or large change.(10) However, variation amongst and between individuals,(10)or 
the measurement error of the measurement tool is not taken into account.(7;8) Also, by 
definition as a single estimate using recall estimation, the global rating of change has an un-
measurable baseline error. Recent approaches have tried to account for this by giving ranges 
for the MCID.(7)  
In recognition of the limitations of each method, we present anchor- and distribution-based 
estimates of the MCID for chronic refractory breathlessness in order to frame the 
categorisation of effect size in the context of patient report. The aim of this paper is to 
quantify the clinically noticeable difference in scores, and not the mechanism whereby the 
intervention effected that change. However, the studies contributing to this work were all 






This was a retrospective analysis of data from a total of 178 clinical trial participants with 
chronic refractory breathlessness from four clinical trials of morphine or oxycodone for the 
management of breathlessness. Of these participants, 35 provided data from separate periods 
of exposure to two different opioids to give a total of 213 sets of data(12) and were treated as 
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two studies for the distribution method calculation.  Baseline characteristics of participants, 
and the NRS/VAS used, are seen in Table 1. Confirmation was obtained that NHS ethical 
permission was not required for secondary analysis of anonymised data.  
The methods of the four contributing studies are described in detail elsewhere.(11-14) In 
summary, three were placebo controlled, randomised, crossover trials, and compared 4 days 
of morphine with 4 days of placebo.(11-13) Oxberry et al added a third arm with 4 days of 
oxycodone.(12) One was a cohort study examining breathlessness response to morphine dose 
increments, with respondents graduating to a pharmacovigilance study in participants with 
breathlessness that improved with morphine.(14) Two studies included only those with CHF; 
in the other studies, participants’ breathlessness was predominantly due to chronic obstructive 
pulmonary disease.(13;14) All participants had chronic refractory breathlessness. 
Three studies used the VAS to measure breathlessness intensity and the others used NRS.  
The NRS intensity scores were represented as equivalent 0 – 100mm in the combined dataset; 
NRS and VAS appear to be reported by patients in a linear fashion in both breathlessness and 




The MCID was calculated using two methods.  
The distribution-based approach calculated the effect size (change after opioid divided by 
standard deviation of baseline scores) in each study. Only data from the opioid arm of the 




Cohen’s guidelines for interpreting small, moderate and large effect sizes were used (sizes 
chosen as  small = 0.25 medium = 0.50, large = 0.80).(17) Assessment of the linear 
relationship between change in breathlessness score and the effect size was explored using a 
linear regression model to determine the change in VAS score equivalent to the three effect 
sizes.  
 
The anchor-based method is from analysis of a pooled dataset of individual participant data 
from randomised controlled trials. The placebo controlled RCTs had data for blinded patient 
preference for the arm of the study which they felt provided better benefit for breathlessness 
for all participants.  Participants in the Oxberry study had data for each opioid intervention 
(morphine and oxycodone arms), but only one set of data on placebo.  
Participant perception of change in breathlessness intensity (day 4 minus baseline VAS 
scores) was examined in relation to preferred study arm (opioid or placebo). The difference 
between the mean change in breathlessness scores in preferred study arm and the mean 






The effect sizes for each study, ranging from 0.1 to 0.6, are shown in Table 2, and the 
regression line shown in Figure 1. The regression equations for the differences in VAS 
breathlessness score and effect sizes 0.25, 0.5, 0.8 are shown below. The slope of the line was 
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statistically significant (p = 0.001) and the percentage variation of the data explained by the 
fitted line was extremely high (R-squared = 0.98). 
 
Small change:  0.2380574 + 23.0974 × (−0.25) = −5.5 
 
Moderate change:  0.2380574 + 23.0974 × (−0.5) = −11.3 
 
Large change:  0.2380574 + 23.0974 × (−0.8) = −18.2 
 
Blinded patient preference calculation 
In total, there were 113 evaluable preference responses from the 93 study participants. A 
stated preference for an intervention arm was given in 93 (62 drug; 31 placebo). Eighteen 
participants had no preference for any intervention arm. The Day 4 minus baseline VAS 
change in the preferred arm (−13mm; SD 24.7mm) was greater than in the non-preferred arm 
(−5mm; SD 19.6mm).  Two did not provide data for the opioid arm, and two did not provide 
data for the placebo arm although data were given for their preferred arm.  The VAS 
difference calculated from 93 datasets with data for both preferred and non-preferred arms 






Using a distribution method, we have estimated the changes in VAS breathlessness intensity 
scores that relate to a small, moderate or large improvement in symptoms using individual 
patient data generated in four studies that evaluated the effect of opioids on chronic refractory 
breathlessness. In keeping with recommendations to estimate MCID by using both a 
distribution method and a patient data anchor method, we have used the blinded patient 
preference data from the placebo-controlled, crossover RCTs. This recognises that there is a 
distinction between a clinically detectable change and a clinically important difference. Our 
data estimates that a reduction in VAS scores of 9mm represents a change that patients 
consider significant enough to warrant choice of one intervention over another. Although 
there are wide confidence intervals and relatively modest sample size for such a calculation, 
the present study includes data from more participants than the only other published anchor-
based estimate in chronic refractory breathlessness. (7) The use of blinded patient preference 
data from RCTs is a novel patient-defined, anchor-based approach and reflects a clinically 
important difference, without the difficulties in analysis inherent relying only on the global 
impression of change. 
Rationale for using both anchor based and distributed based methods 
The distinction between a detectable difference and a clinically important difference is 
difficult to deduce from distribution methods alone. (17) Cohen’s grading system was 
devised in the context of psychological research that shares parallel challenges of multi-
factorial and subjective study endpoints, so its application to chronic breathlessness is 
reasonable. 
Although the size of the clinical effect can be estimated using the grading suggested by 
Cohen, this can be criticised as being fairly arbitrary. The terms “small”, “moderate” and 
“large” are relative to each other and will be different for individuals and perhaps also within 
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sub-populations. This should be taken into consideration when interpreting results. This is 
illustrated by data from a total of 95 participants from five studies in people with COPD 
where a VAS was used as the outcome measurement (18); three studies of pulmonary 
rehabilitation (19-21); and one each in oxygen supplementation(22); and (23)  lung reduction 
surgery. Ries et al found effect sizes ranging between 0.48 (11.9 mm) and 1.76 (30.3mm) 
equating to a moderate to large improvements.(18) However, the participants varied 
considerably with regard to gender split (one study was solely of men), baseline intensity of 
breathlessness (25mm to 79.6mm) and intervention.(18) For example, a patient’s perception 
of what constitutes a large change may depend on how long they have been living with daily 
breathlessness, limitations to their activities of daily living due to breathlessness and the 
burden of the intervention. Net clinically important benefit may be different for those with 
severe baseline breathlessness who underwent lung reduction surgery as a last desperate 
attempt to reduce symptoms, when compared to those with similar baseline breathlessness 
intensity who attended pulmonary rehabilitation classes even though both approaches have 
been demonstrated to have large effects.  
Thus anchor based methods, with their direct use of the patient’s subjective experience with 
regard to whether the symptom is worse or better, adds further information to the effect size, 
helping to confirm that the detected difference does indeed have clinical significance to the 
patient. In our data, we can see the mean change that was considered by study participants to 
be significant enough to warrant a choice between two interventions, and the figure of 9mm 
lies very near the ‘moderate effect size’ as calculated by the distribution method. 
Comparison with other published estimates for the MCID for breathlessness 
The MCID for acute breathlessness due to asthma(24) or acute decompensated heart 
failure(25) has been estimated using anchor based methods (global impression of change), 
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where a difference of 21.1 mm and 22mm respectively on a 100mm VAS was found to be 
equivalent to subjectively “feeling a little less breathless”. Our data indicate that the MCID is 
less than this for people with chronic breathlessness. These people had more intense 
breathlessness when they were assessed initially and might expect, at least in asthma, to 
return to no breathlessness when successfully treated.  In acute breathlessness, both absolute 
and relative improvements were almost double the levels needed in chronic breathlessness 
(where there may be little expectation of breathlessness returning to zero). In addition, acute 
breathlessness is usually accompanied by severe distress and is likely to represent a very 
different patient experience than that of a person who experiences breathlessness daily at rest 
or on minimal exertion over many months or years.  
People with chronic breathlessness tend to adapt to limitations caused by breathlessness over 
time in a resourceful and stoical manner, which can render it less visible as a symptom.(26) 
Medical care may only be sought when there is a crisis, with little expectation that 
interventions could provide clinically relevant benefit in its chronic state when a change in 
intensity equating to a smaller change in the absolute VAS score could have a clinically 
meaningful benefit for individuals coping with daily breathlessness.(27) In addition, 
clinicians may perceive chronic breathlessness which persists despite optimally tolerated 
management of the underlying disease as difficult to treat and inevitable.(28;29) Such 
therapeutic nihilism may mean that optimal assessment and treatment does not occur, and 
clinical focus is directed to other symptoms considered more responsive to interventions. 
Recognition that even a relatively small improvement in the intensity of breathlessness is 
perceived by the patient as a useful change may drive a more systematic approach to 
breathlessness management. 
Comparison with other published estimates for the MCID in chronic breathlessness 
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Ries et al estimated that a change of 10 – 20 mm VAS represented a moderate change using 
their distribution methods.(18) Our data supports this, as 10mm change in VAS is just below 
the value of a moderate change (distribution method) and just greater than the clinically 
important difference measured by patient anchor. Oxberry et al reported a moderate effect 
size (0.5) using a distribution method.(7)  Assuming 10mm VAS is equivalent to 1 point 
NRS, values from both distribution (5.5mm small; 11.3mm moderate; 18.2mm large) and 
anchor methods (9mm) in this paper fall within the range (0.5 – 2.0  for average/24 hours  
NRS score) calculated from the anchor based estimation in the Oxberry study. 
Our combined data used VAS/NRS measures framed as “breathlessness now” and “average 
breathlessness over the past 24 hours”. Given these are both measures in the context of 
chronic daily breathlessness, rather than acute exacerbations (we did not use the “worst 
breathlessness over the past 24 hours” measure that we also had in the Oxberry dataset) we 
have made the assumption that an absolute change in either will reflect a clinically important 
difference in chronic refractory breathlessness. However, this should be taken into account 
when interpreting our findings.  
The consensus statement recommends that a clinically important difference for chronic 
refractory breathlessness scores is 1 point on an NRS scale or 10mm on a VAS scale.(30) Our 
data supports this value confirming that this level of improvement should be the therapeutic 
target. Studies of chronic refractory breathlessness should be powered to detect this 
difference. 
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Figure 1. Regression line of effect size (change in VAS score divided by standard 
deviation of baseline scores) and patient rated change in breathlessness score (VAS) 
from the contributing studies (Table 2) 
Table 1.  Baseline data from contributing studies in order to calculate a distribution-based estimate of minimal clinically important 
difference in dyspnoea intensity scores for people with chronic refractory dyspnoea.  
 
Variable  Abernethy (13) Currow (14) Johnson (11) Oxberry        
(12) 
Morphine  
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VAS/NRS scale  100 mm VAS; 0 mm = ‘‘no breathlessness’’; 100 
mm = ‘‘worst imaginable breathlessness.’’ 
0-10 NRS; average breathlessness 
over last 24 hours. Verbal anchors 
as for Currow and Abernethy 
  
 
SD  standard deviation; HF heart failure; COPD Chronic obstructive pulmonary disease; MND motor neurone disease; RLD restrictive lung 
disease 






















Abernethy −2.5 42 19 23.2 −0.11 
Currow −7.0 48` 18.0 21.8 −0.32 
Johnson −12.0 35 27.0 24.6 −0.48 
Oxberry 
(morphine) 
−4.0 41 25.1 19.7 −0.20 
Oxberry 
(oxycodone) 
−12.9 48 21.9 21.7 −0.60 
